[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559019":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":54,"collaborators":56,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":31,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":31,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":31,"overallStatus":35,"whyStopped":31,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Disitamab Vedotin Combined with Cisplatin","EXPERIMENTAL","Locally advanced cervical cancer patient was treated with Disitamab Vedotin combined with Cisplatin for neoadjuvant therapy.",[13],"Drug: Disitamab Vedotin and Cisplatin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Disitamab Vedotin and Cisplatin","Disitamab Vedotin: 2mg\u002FKg,ivdrip, 3 weeks\u002Fcycle,3 cycles. Cisplatin: 75-80mg\u002Fm2, ivdrip, 3 weeks\u002Fcycle,3 cycles.",[9],[21],"Aidixi",[23],{"name":24,"affiliation":5,"role":25},"Kun Song","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Hualei Bu","CONTACT","86-0531-82169269",null,"buhualei@email.sdu.edu.cn",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Jinan","Shandong","250012","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.99722,36.66833,{"lat":45,"lon":44},[48,51],{"name":49,"role":29,"phone":50,"phoneExt":31,"email":32},"Hualei Bu, Dr.","86 18560089466",{"name":52,"role":29,"phone":31,"phoneExt":31,"email":53},"Yana Ma, Dr.","202462000612@email.sdu.edu.cn",{"type":25,"investigatorFullName":24,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Chief Physician",[57],{"name":58,"class":59},"RemeGen Co., Ltd.","INDUSTRY","100559019","neoadjuvant-therapy-in-cervical-cancer-100559019",false,"NCT06558682","Neoadjuvant Therapy in Cervical Cancer","Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial","Inclusion Criteria:\n\n* Clinical diagnosis of cervical squamous cell carcinoma\n* HER-2 positive\n\nExclusion Criteria:\n\n* Cervical adenocarcinoma","FEMALE","18 Years","70 Years",{"count":71,"type":72},48,"ESTIMATED","INTERVENTIONAL",[75],"NA","In the comprehensive dataset of clinical diagnoses and treatments for cervical cancer in China, 49.8% of patients with stage IB3 and IIA2 receive surgical intervention following neoadjuvant chemotherapy. This indicates a pressing need to optimize neoadjuvant chemotherapy regimens for locally advanced cervical cancer. While paclitaxel combined with cisplatin is the conventional approach, 9.8% to 30.6% of patients demonstrate suboptimal responses, with a pathological complete response rate of approximately 10%.\n\nCurrently, the efficacy of antibody-drug conjugates in neoadjuvant chemotherapy for cervical cancer remains unexplored. This study seeks to address this gap by evaluating the combination of Disitamab Vedotin and Cisplatin in patients with stage IB3 and IIA2 cervical cancer with positive HER2 expression.The study will assess the impact of this regimen on pathological complete response rates, surgical complications, surgical resection rates, and overall survival.",[78],"Uterine Cervical Neoplasms","2025-03-26",{"date":81,"type":82},"2025-04-01","ACTUAL",{"date":84,"type":82},"2024-10-20",{"date":86,"type":72},"2026-10-01",{"name":5,"class":6},1]